Every Nose Counts: A New Influenza Vaccine for All Healthy Schoolchildren?

Clinical Pediatrics

Volumn 43, Issue 1, 2004, Pages 35-41

  Gaglani, Manjusha J ^a   Herschler, Gayla B ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC ANALGESIC AGENT; INFLUENZA VACCINE;

ABDOMINAL PAIN; AGE DISTRIBUTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG FEVER; DRUG INDICATION; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LICENSING; NOSE CONGESTION; REVIEW; RHINORRHEA; RISK BENEFIT ANALYSIS; SCHOOL CHILD; SEASONAL VARIATION; SIDE EFFECT; VACCINATION REACTION; VIRUS STRAIN; VIRUS TRANSMISSION; VOMITING; WINTER;

ADMINISTRATION, INTRANASAL; CHILD; CHILD, PRESCHOOL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TREATMENT OUTCOME;

EID: 1642540122     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280404300105     Document Type: Review

References (36)

1. Centers for Disease Control and Prevention. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2002;51(RR-3):1-31.
2. Couch RB. Prevention and treatment of influenza. N Engl J Med. 2000;343:1778-1787.
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
4. Neuzil KM, Hohlbein RN, Yuwei Z. Illness among schoolchildren during influenza season. Arch Pediatr Adolesc Med. 2002;156:986.
5. Patriarca PA. New options for prevention and control of influenza. JAMA. 1999;282:75-77.
6. Glaser CA, Gilliam S, Thompson WM, et al. Medical care capacity for influenza outbreaks, Los Angeles. Emerg Infect Dis. 2002;8:569-574.
7. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659-671.
8. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64-76.
9. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
10. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
11. Gaglani MJ, Riggs MR, Kamenicky C, et al. A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway disease. Pediatr Infect Dis J. 2001;20:1155-1160.
12. Gaglani MJ. Rationale and approach to target children with asthma for annual influenza immunization. Semin Pediatr Infect Dis. 2002;13:97-103.
13. Mendelman PM, Cordova J, Cho I. Safety, efficacy, and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and adults. Vaccine. 2001;19:2221-2226.
14. Piedra PA. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis. 2002;13:90-96.
15. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
16. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
17. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000;181:1133-1137.
18. Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002;110:662.
19. Gaglani MJ, Piedra PA, Riggs MW, et al. Safety of the trivalent, cold-adapted, influenza virus vaccine (CAIV-T) in a subgroup of children with history of mild intermittent wheezing/asthma/reactive airway disease (RAD) in a community-based, non-randomized, open-label trial [abstract 1382]. Presented at the Pediatric Academic Societies, Baltimore, Maryland; April 29, 2001.
20. Piedra PA, Gaglani M, Herschler G, et al. Safety and effectiveness of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. In: Osterhaus ADME, ed. The World Congress on Options for the Control of Influenza IV. Amsterdam: Elsevier Science; 2001:939-943.
21. Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis. 2001;20:740-746.
22. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20:1124-1131.
23. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21:44-48.
24. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated, intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282:137-144.
25. Gaglani MJ, Piedra PA, Herschler GB, et al. Effectiveness of the trivalent, cold-adapted influenza virus vaccine (CAIV-T) against the 2000-01 influenza A (H1N1) epidemic in a community-based, non-randomized open-label trial in healthy children [abstract 1639]. Presented at the Pediatric Academic Societies, Baltimore, Maryland; May 6, 2002.
26. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics. 1999;103:e73.
27. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics. 2000;106:973-976.
28. Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics. 2001;108:e24.
29. Monto AS, Davenport FM, Napier JA, et al. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis. 1970;122:16-25.
30. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344:889-896.
31. Longini IM Jr, Halloran EM, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine. 2000;18:1902-1909.
32. Glezen WP. Influenza vaccination for healthy children. Curr Opin Infect Dis. 2002;15:283-287.
33. Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs. 2002;4:65-71.
34. Herschler G, Griffith M, Gelsthorpe J, et al. Patient enrollment into large, time sensitive trials. SoCRA Source. 2001:40.
35. Grabenstein JD. Nasal influenza vaccine: a bridge to full-service vaccine delivery by pharmacists. J Am Pharm Assoc. 2001;41:473.
36. Humiston SG, Iwane M, Schaffer SJ, et al. Physician perceptions of the feasibility of universal influenza vaccination for young children [abstract 907]. Presented at the Pediatric Academic Societies, Baltimore, Maryland; May 5, 2002.